Research & Treatment News

Encouraging Trial Results for Hep C Drug Faldaprevir

May 2, 2013 5 Comments

Data from Boehringer Ingelheim’s Phase III trial of faldaprevir claims high success rates for treatment-naïve patients with Hepatitis C genotype 1.

Interferon-Free Study Boosts Belief in Sofosbuvir

Apr 25, 2013

Sofosbuvir and ribavirin show a high response rate for Hepatitis C genotypes 2 and 3 in a Phase 3 study at Weil Cornell Medical Center.

Did Tulsa Dentist Infect Nearly 60 Patients with Hep C?

Apr 25, 2013

Poor sterilization techniques have landed a Tulsa dentist office in hot water, especially since 57 former patients tested positive for Hepatitis C.

The Dark Side of Telaprevir

Apr 23, 2013 58 Comments

Telaprevir has helped many people conquer the Hepatitis C virus – but this medication is accompanied by a risk that should be widely known.

Hope for Hep C from Immune Blocking Discovery

Apr 19, 2013

The polar opposite of what scientists previously thought, UCLA researchers have found that blocking an immune system protein could help the body clear a chronic viral infection.

Hep C Research Chimps May Be Switched Out for Mice

Apr 19, 2013

Efforts to spare chimps from medical research is making progress, including a potential rodent alternative for studying Hepatitis C.

Hep C Studies on Faldaprevir Will Be Heard at EASL

Apr 16, 2013

Studies with and without interferon on faldaprevir (Boehringer Ingelheim’s Hepatitis C drug), will be presented at the EASL annual liver meeting this month.

New Drug Application Submitted for Gilead’s Sofosbuvir

Apr 16, 2013 56 Comments

Gilead has taken the next step for bringing an all-oral Hepatitis C treatment to fruition, submitting a new drug application to the FDA for their nucleotide analogue, sofosbuvir.